Brought to you by 
Roche brings in RNAi capabilities through Alnylam deal' Arrowhead takes over deal
03 Dec 2015
Executive Summary
Alnylam Pharmaceuticals (develops medicines that turn off disease-causing genes) has granted Roche nonexclusive rights to its RNA interference (RNAi) platform. The Big Pharma is also buying Alnylam's Kulmbach, Germany, R&D site and will convert it into a Center of Excellence focusing on RNAi therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche brings in RNAi capabilities through Alnylam deal' Arrowhead takes over deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice